Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $6.8 million for Q3 2025.

• In Q3 2025, Other Non-Current Liabilities rose 9.58% year-over-year to $6.8 million; the TTM figure through Sep 2025 stood at $6.8 million (up 9.58% YoY), while the FY2024 annual figure was $6.4 million, up 10.39% from the prior year.
• Other Non-Current Liabilities was $6.8 million for Q3 2025 at Atea Pharmaceuticals, up from $6.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $6.8 million in Q3 2025 to a low of $29000.0 in Q2 2021.
• Historically, Other Non-Current Liabilities has averaged $5.3 million across 5 years, with a median of $5.9 million in 2021.
• Biggest YoY gain for Other Non-Current Liabilities was 20617.24% in 2022; the steepest drop was 11.41% in 2022.
• A 5-year view of Other Non-Current Liabilities shows it stood at $5.9 million in 2021, then decreased by 11.41% to $5.3 million in 2022, then grew by 9.57% to $5.8 million in 2023, then gained by 10.39% to $6.4 million in 2024, then grew by 6.91% to $6.8 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $6.8 million (Q3 2025), $6.6 million (Q2 2025), and $6.5 million (Q1 2025), per Business Quant data.